Shenzhen, China
MGI Tech Co., Ltd. (MGI) has quickly established itself as a frontrunner in the field of life sciences since its founding in 2016. With headquarters in China, the company focuses on innovations in Biotechnology, Health Care, and Life Sciences.
MGI's distinctive capability in developing and mass-producing clinical-grade gene sequencers sets it apart from competitors, addressing capacities from Gb to Tb levels, which is crucial for applications in precision medicine and other industries. The company provides a full spectrum of digital equipment for various sectors, showcasing its comprehensive approach and commitment to driving innovation.
The company's growth and strategic global presence are further bolstered by a substantial $1.00B Series B investment secured on 28 May 2020. Investors include Green Pine Capital Partners, CITIC Securities, and CPE Capital, among others, demonstrating strong financial backing and confidence in MGI's trajectory. With its cutting-edge products and global impact, MGI is well-positioned to continue shaping the future of life sciences.
